The Changing CDMO Landscape: Single-Use Technology, End-to-End Fill Finish Needs and Growth of Cell and Gene
Christoph Winterhalter, Chief Business Officer of AGC Biologics, highlights trends in single-use technology, the CDMO’s new fill-finish capabilities, facility expansions, the potential impact of the U.S. Biosecure Act, and the growing cell and gene market.
Watch this video to learn more:
- AGC Biologics’ new fill and finish offering for protein biologics
- Facility expansions and partnerships to address common trends, like the U.S. Biosecure Act
- The power of single-use technology for developers
- The CDMOs growing cell and gene commercial track record
Recent Videos
Related Content
